Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK112 and AK119 with or without chemotherapy in advanced pMMR/MSS colorectal cancer
CTR20230869Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- May 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, ambuzutinib in colorectal adenocarcinoma, sponsored by Akeso, Inc.. Started May 2023; status: active.
02
Drugs
ivonescimabambuzutinib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20230869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230869.